Abstract
In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous thromboembolic events in patients who have undergone total hip- or knee-replacement surgery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008).
Geerts, W. H. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 338S–400S (2004).
Di Nisio, M. et al. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028–1040 (2005).
Hauel, N. H. et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 45, 1757–1766 (2002).
Wienen, W. et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb. Haemost. 98, 333–338 (2007).
European Medicines Agency (EMEA). European Public Assessment Report — Pradaxa. EMEA web site [online], (2008).
Eriksson, B. I. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Thromb. Haemost. 5, 2178–2185 (2007).
Eriksson, B. I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949–956 (2007).
IMS, MIDAS Quantum (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
B.I.E. has received consulting fees from Bayer Healthcare, Boehringer Ingelheim and Astellas.
Rights and permissions
About this article
Cite this article
Eriksson, B., Smith, H., Yasothan, U. et al. Dabigatran etexilate. Nat Rev Drug Discov 7, 557–558 (2008). https://doi.org/10.1038/nrd2622
Issue Date:
DOI: https://doi.org/10.1038/nrd2622
This article is cited by
-
Synthesis and biological evaluation of novel dabigatran derivatives as thrombin inhibitors
Research on Chemical Intermediates (2016)
-
Bacterial proteolytic complexes as therapeutic targets
Nature Reviews Drug Discovery (2012)
-
Heparin-induced effects of prothrombin complex concentrates in thromboelastometry
Wiener klinische Wochenschrift (2012)
-
Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment
Neurocritical Care (2012)
-
Emerging principles in protease-based drug discovery
Nature Reviews Drug Discovery (2010)